Colorectal Cancer malady

Genetic diseases, Cancer diseases, Gastrointestinal diseases, Rare diseases categories

Aliases & Classifications for Colorectal Cancer

About this section

Aliases & Descriptions for Colorectal Cancer:

Name: Colorectal Cancer 46 30 8 64 10 44 32 61
Colon Carcinoma 8 44 61
Colon Cancer 46 8 44
Colon Cancer, Somatic 46 9
Colorectal Carcinoma 44 61
Neoplasm of Colon 20 22
Colonic Adenoma Recurrence, Reduced Risk of 46
Colorectal Cancer, Somatic 46
Malignant Tumor of Colon 61
Carcinoma of Colon 8
Colonic Carcinoma 8
Colonic Neoplasms 61


Summaries for Colorectal Cancer

About this section
OMIM:46 Colorectal cancer is a heterogeneous disease that is common in both men and women. In addition to lifestyle and... (114500) more...

MalaCards based summary: Colorectal Cancer, also known as colon carcinoma, is related to lynch syndrome and adenoma, and has symptoms including uterine leiomyosarcoma, renal cell carcinoma and hereditary nonpolyposis colorectal carcinoma. An important gene associated with Colorectal Cancer is DCC (deleted in colorectal carcinoma), and among its related pathways are Pathways in cancer and Endometrial cancer. The drugs carmustine and lomustine and the compounds serine and tyrosine have been mentioned in the context of this disorder. Affiliated tissues include the colon, colon and liver, and related mouse phenotypes are mortality/aging and cellular.

Disease Ontology:8 A colorectal cancer that is located in the colon.

MedlinePlus:32 The colon and rectum are part of the large intestine. colorectal cancer occurs when tumors form in the lining of the large intestine. it is common in both men and women. the risk of developing colorectal cancer rises after age 50. you're also more likely to get it if you have colorectal polyps, a family history of colorectal cancer, ulcerative colitis or crohn's disease, eat a diet high in fat, or smoke. symptoms of colorectal cancer include diarrhea or constipation a feeling that your bowel does not empty completely blood (either bright red or very dark) in your stool stools that are narrower than usual frequent gas pains or cramps, or feeling full or bloated weight loss with no known reason fatigue nausea or vomiting because you may not have symptoms at first, it's important to have screening tests. everyone over 50 should get screened. tests include colonoscopy and tests for blood in the stool. treatments for colorectal cancer include surgery, chemotherapy, radiation, or a combination. surgery can usually cure it when it is found early. nih: national cancer institute

Wikipedia:64 Colorectal cancer (also known as colon cancer, rectal cancer or bowel cancer) is the development of... more...

Related Diseases for Colorectal Cancer

About this section

Diseases in the Colorectal Cancer family:

Colorectal Cancer 1 Colorectal Cancer 12
Colorectal Cancer 3 Colorectal Cancer 10
Familial Colorectal Cancer

Diseases related to Colorectal Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 461)
idRelated DiseaseScoreTop Affiliating Genes
1lynch syndrome32.9MLH3, APC, TP53, BRAF, NRAS
2adenoma32.9TP53, APC, ODC1, PTPRJ, BRAF, CCND1
3adenocarcinoma32.4PIK3CA, ODC1, APC, TP53, BRAF, EP300
4melanoma32.4BRAF, TP53, ODC1, PIK3CA, EP300, AKT1
5adenomatous polyposis coli32.0APC, CTNNB1
6lung cancer32.0TP53, BRAF, CCND1, BAX
7leukemia31.9PIK3CA, ODC1, TP53, EP300, AKT1, CCND1
8breast cancer31.9CCND1, TP53
9retinoblastoma31.8PIK3CA, ODC1, APC, TP53, EP300, AKT1
10endometrial cancer31.8CTNNB1, BRAF, TP53
11colon adenocarcinoma31.7BUB1B, ODC1, BAX, CTNNB1
12stomach cancer31.7EP300, AKT1, CCND1, BAX, CTNNB1, BRAF
13hepatocellular carcinoma31.6CTNNB1, PIK3CA
14prostate cancer31.5ODC1, AKT1, BAX, CTNNB1
15cholangiocarcinoma31.4PIK3CA, TP53, BRAF, NRAS
16myeloma31.4FGFR3, BAX, CCND1, AKT1
17pancreatic cancer31.4AKT1, CCND1, CTNNB1
18sarcoma31.4ODC1, TP53, BRAF, EP300, NRAS
19mismatch repair cancer syndrome31.3CTNNB1, APC
20neuroblastoma31.3TP53, AKT1
21esophageal cancer31.2BAX, CCND1
22thyroid cancer31.2PIK3CA, PTPRJ, APC, BRAF, FGFR3
23glioblastoma31.2PIK3CA, ODC1, TP53, AKT1, CCND1, BAX
24mental retardation31.2BRAF, EP300, AKT1, FGFR3
25chronic lymphocytic leukemia31.1BAX, CCND1, TP53
26glioblastoma multiforme31.1PIK3CA, ODC1, TP53, BAX
27gallbladder cancer31.0APC, TP53, NRAS
28ataxia-telangiectasia31.0BAX, TP53, PIK3CA
29papilloma31.0FGFR3, TP53, ODC1
30desmoid disease, hereditary30.9APC, CTNNB1
31gastric cancer, somatic30.9PIK3CA, APC
32polyposis, juvenile intestinal30.8APC
33multiple myeloma30.8CCND1, FGFR3
34fibromatosis30.5CTNNB1, APC
35familial colorectal cancer11.1
37tongue squamous cell carcinoma11.0PIK3CA, AURKA, ODC1, APC, TP53, EP300
39lung cancer susceptibility 310.9PIK3CA, TP53, BRAF, CCND1, BAX, CTNNB1
40ovarian cancer, somatic10.9PIK3CA, TP53, BRAF, CCND1, BAX, CTNNB1
41burkitt lymphoma10.9PIK3CA, ODC1, TP53, EP300, AKT1, CCND1
42thyroid carcinoma, papillary10.9APC, BRAF, CCND1, BAX, CTNNB1
43cervical cancer, somatic10.8PIK3CA, TP53, EP300, BAX, FGFR3
44malignant glioma10.8PIK3CA, AURKA, ODC1, TP53, BRAF, AKT1
45thyroid cancer, anaplastic10.8CTNNB1, BRAF, TP53, PIK3CA
47laryngeal squamous cell carcinoma10.8AURKA, TP53, CCND1, BAX
48brain cancer10.8PIK3CA, APC, TP53, AKT1
49gastric adenocarcinoma10.8PIK3CA, ODC1, APC, BAX, CTNNB1
50thyroid adenoma10.8PIK3CA, APC, BRAF

Graphical network of the top 20 diseases related to Colorectal Cancer:

Diseases related to colorectal cancer

Symptoms for Colorectal Cancer

About this section

Symptoms by clinical synopsis from OMIM:


Clinical features from OMIM:


HPO human phenotypes related to Colorectal Cancer:

id Description Frequency HPO Source Accession
1 uterine leiomyosarcoma HP:0002891
2 renal cell carcinoma HP:0005584
3 hereditary nonpolyposis colorectal carcinoma HP:0006716
4 transitional cell carcinoma of the bladder HP:0006740
5 neoplasm of the stomach HP:0006753

Drugs & Therapeutics for Colorectal Cancer

About this section

FDA approved drugs:

(show all 11)
id Drug Name Active Ingredient(s)13 Pharmaceutical Company Approval Date
Avastin13 38 BEVACIZUMAB Genentech Approved July 2009
FDA Label: Avastin
Malady that Drug Treats: renal cell carcinoma & Colorectal Cancer
Indications and Usage:13 Avastin is a vascular endothelial growth factor-specific angiogenesis; inhibitor indicated for the treatment of:; Metastatic colorectal cancer, with intravenous 5-fluorouracil-based; chemotherapy for first- or second-line treatment. (1.1); Metastatic colorectal cancer, with fluoropyrimidine- irinotecan- or; fluoropyrimidine-oxaliplatin-based chemotherapy for second-line; treatment in patients who have progressed on a first-line Avastincontaining; regimen. (1.1); Non-squamous non-small cell lung cancer, with carboplatin and paclitaxel; for first line treatment of unresectable, locally advanced, recurrent or; metastatic disease. (1.2); Glioblastoma, as a single agent for adult patients with progressive disease; following prior therapy. (1.3); -Effectiveness based on improvement in objective response rate. No data; available demonstrating improvement in disease-related symptoms or; survival with Avastin.; Metastatic renal cell carcinoma with interferon alfa (1.4); Cervical cancer, in combination with paclitaxel and cisplatin or paclitaxel; and topotecan in persistent, recurrent, or metastatic disease. (1.5); Platinum-resistant recurrent epithelial ovarian, fallopian tube or primary; peritoneal cancer, in combination with paclitaxel, pegylated liposomal; doxorubicin or topotecan (1.6) Limitation of Use: Avastin is not indicated for adjuvant treatment of colon; cancer. (1.1)
DrugBank Targets:11 1. Vascular endothelial growth factor A; 2. Low affinity immunoglobulin gamma Fc region receptor III-B; 3. Complement C1r subcomponent; 4. Complement C1q subcomponent subunit A; 5. Complement C1q subcomponent subunit B; 6. Complement C1q subcomponent subunit C; 7. Low affinity immunoglobulin gamma Fc region receptor III-A; 8. High affinity immunoglobulin gamma Fc receptor I; 9. Low affinity immunoglobulin gamma Fc region receptor II-a; 10. Low affinity immunoglobulin gamma Fc region receptor II-b; 11. Low affinity immunoglobulin gamma Fc region receptor II-c
Mechanism of Action:13 
Target: VEGF
Action: inhibitor
FDA: Bevacizumab binds VEGF and prevents the interaction of VEGF to its receptors (Flt-1 and KDR); 697 on the surface of endothelial cells. The interaction of VEGF with its receptors leads to endothelial; 698 cell proliferation and new blood vessel formation in in vitro models of angiogenesis. Administration; 699 of bevacizumab to xenotransplant models of colon cancer in nude (athymic) mice caused reduction; 700 of microvascular growth and inhibition of metastatic disease progression
Campostar13 38 IRINOTECAN HYDROCHLORIDE Pharmacia & Upjohn Approved June 1996
FDA Label: Campostar
Malady that Drug Treats: metastatic colorectal cancer
Indications and Usage:13 CAMPTOSAR is a topoisomerase inhibitor indicated for:; First-line therapy in combination with 5-fluorouracil and leucovorin for; patients with metastatic carcinoma of the colon or rectum. (1); Patients with metastatic carcinoma of the colon or rectum whose disease; has recurred or progressed following initial fluorouracil-based therapy. (1)
DrugBank Targets:11 1. DNA topoisomerase I, mitochondrial; 2. DNA topoisomerase 1
Mechanism of Action:13 
Target: topoisomerase I-DNA complex
Action: inhibitor of repairs to DNA
FDA: Irinotecan is a derivative of camptothecin. Camptothecins interact specifically with the enzyme; topoisomerase I, which relieves torsional strain in DNA by inducing reversible single-strand; breaks. Irinotecan and its active metabolite SN-38 bind to the topoisomerase I-DNA complex; and prevent religation of these single-strand breaks. Current research suggests that the; cytotoxicity of irinotecan is due to double-strand DNA damage produced during DNA synthesis; when replication enzymes interact with the ternary complex formed by topoisomerase I, DNA,; and either irinotecan or SN-38. Mammalian cells cannot efficiently repair these double-strand; breaks.
CEA-Scan13 Immunomedics Approved April 1996
FDA Label: -
Malady that Drug Treats: colorectal cancer
Indications and Usage:13 -
DrugBank Targets:11 1. Carcinoembryonic antigen-related cell adhesion molecule 1
Mechanism of Action:13 
Target: carcinoembryonic antigen (""CEA"")
Action: marks
FDA: -
Eloxatin13 38 OXALIPLATIN Sanofi-aventis Approved August 2002
FDA Label: Eloxatin
Malady that Drug Treats: Metastatic colon or rectum carcinomas that have recurred or progressed within six months folowing first-line treatment
Indications and Usage:13 ELOXATIN is a platinum-based drug used in combination with infusional 5-; fluorouracil /leucovorin, which is indicated for:; adjuvant treatment of stage III colon cancer in patients who have; undergone complete resection of the primary tumor. (1); treatment of advanced colorectal cancer. (1)
DrugBank Targets:11 1. DNA
Mechanism of Action:13 
Target: DNA replication and transcription
Action: inhibitor
FDA: Oxaliplatin undergoes nonenzymatic conversion in physiologic solutions to active derivatives via; displacement of the labile oxalate ligand. Several transient reactive species are formed, including; monoaquo and diaquo DACH platinum, which covalently bind with macromolecules. Both interand; intrastrand Pt-DNA crosslinks are formed. Crosslinks are formed between the N7 positions of; two adjacent guanines (GG), adjacent adenine-guanines (AG), and guanines separated by an; intervening nucleotide (GNG). These crosslinks inhibit DNA replication and transcription.; Cytotoxicity is cell-cycle nonspecific.; In vivo studies have shown antitumor activity of oxaliplatin against colon carcinoma. In; combination with 5-fluorouracil, oxaliplatin exhibits in vitro and in vivo antiproliferative activity; greater than either compound alone in several tumor models [HT29 (colon), GR (mammary), and; L1210 (leukemia)].
Erbitux13 38 CETUXIMAB Imclone, Bristol-Myers Squibb Approved February 2004
FDA Label: Erbitux
Malady that Drug Treats: Colorectal Cancer
Indications and Usage:13 Erbitux® is an epidermal growth factor receptor (EGFR) antagonist indicated; for treatment of:; Head and Neck Cancer; Locally or regionally advanced squamous cell carcinoma of the head; and neck in combination with radiation therapy. (1.1, 14.1); Recurrent locoregional disease or metastatic squamous cell carcinoma; of the head and neck in combination with platinum-based therapy with; 5-FU. (1.1, 14.1); Recurrent or metastatic squamous cell carcinoma of the head and neck; progressing after platinum-based therapy. (1.1, 14.1); Colorectal Cancer; K-Ras wild-type, EGFR-expressing, metastatic colorectal cancer as; determined by FDA-approved tests; in combination with FOLFIRI for first-line treatment,; in combination with irinotecan in patients who are refractory to; irinotecan-based chemotherapy,; as a single agent in patients who have failed oxaliplatin- and; irinotecan-based chemotherapy or who are intolerant to irinotecan.; (1.2, 5.7, 12.1, 14.2); Limitation of Use: Erbitux is not indicated for treatment of Ras-mutant; colorectal cancer. (5.7, 14.2)
DrugBank Targets:11 1. Epidermal growth factor receptor; 2. Low affinity immunoglobulin gamma Fc region receptor III-B; 3. Complement C1r subcomponent; 4. Complement C1q subcomponent subunit A; 5. Complement C1q subcomponent subunit B; 6. Complement C1q subcomponent subunit C; 7. Low affinity immunoglobulin gamma Fc region receptor III-A; 8. Complement C1s subcomponent; 9. High affinity immunoglobulin gamma Fc receptor I; 10. Low affinity immunoglobulin gamma Fc region receptor II-a; 11. Low affinity immunoglobulin gamma Fc region receptor II-b; 12. Low affinity immunoglobulin gamma Fc region receptor II-c
Mechanism of Action:13 
Target: binding of epidermal growth factor (EGF) and other ligands to epidermal growth factor receptor (EGFR, HER1, c-ErbB-1)
Action: inhibitor
FDA: The epidermal growth factor receptor (EGFR, HER1, c-ErbB-1) is a transmembrane; glycoprotein that is a member of a subfamily of type I receptor tyrosine kinases including EGFR,; HER2, HER3, and HER4. The EGFR is constitutively expressed in many normal epithelial; tissues, including the skin and hair follicle. Expression of EGFR is also detected in many human; cancers including those of the head and neck, colon, and rectum. ; ; ; Cetuximab binds specifically to the EGFR on both normal and tumor cells, and competitively; inhibits the binding of epidermal growth factor (EGF) and other ligands, such as transforming; growth factor-alpha. In vitro assays and in vivo animal studies have shown that binding of; cetuximab to the EGFR blocks phosphorylation and activation of receptor-associated kinases,; resulting in inhibition of cell growth, induction of apoptosis, and decreased matrix; metalloproteinase and vascular endothelial growth factor production. Signal transduction through; the EGFR results in activation of wild-type Ras proteins, but in cells with activating Ras somatic; mutations, the resulting mutant Ras proteins are continuously active regardless of EGFR; regulation.; In vitro, cetuximab can mediate antibody-dependent cellular cytotoxicity (ADCC) against certain; human tumor types. In vitro assays and in vivo animal studies have shown that cetuximab; inhibits the growth and survival of tumor cells that express the EGFR. No anti-tumor effects of; cetuximab were observed in human tumor xenografts lacking EGFR expression. The addition of; cetuximab to radiation therapy or irinotecan in human tumor xenograft models in mice resulted; in an increase in anti-tumor effects compared to radiation therapy or chemotherapy alone.
Fusilev13 LEVOLEUCOVORIN CALCIUM Spectrum Pharmaceuticals Approved March of 2008
FDA Label: Fusilev
Malady that Drug Treats: rescue after high-dose methotrexate therapy in osteosarcoma and to reduce the toxicity of methotrexate
Indications and Usage:13 Fusilev is a folate analog indicated for:; Rescue after high-dose methotrexate therapy in osteosarcoma.; Diminishing the toxicity and counteracting the effects of impaired; methotrexate elimination and of inadvertent overdosage of folic acid; antagonists.; Use in combination chemotherapy with 5-fluorouracil in the palliative; treatment of patients with advanced metastatic colorectal cancer.(1); Limitations of Use; Fusilev is not approved for pernicious anemia and megaloblastic anemias.; Improper use may cause a hematologic remission while neurologic; manifestations continue to progress. (1.1)
DrugBank Targets:11 1. Thymidylate synthase
Mechanism of Action:13 
Target: therapeutic and toxic effects of folic acid; antagonists / therapeutic and toxic effects of fluoropyrimidines used in cancer therapy
Action: counteract/enhance
FDA: 12.1.1 Levoleucovorin effects during high-dose methotrexate therapy; Levoleucovorin is the pharmacologically active isomer of 5-formyl tetrahydrofolic acid. Levoleucovorin does not require; reduction by the enzyme dihydrofolate reductase in order to participate in reactions utilizing folates as a source of  onecarbon ; moieties. Administration of levoleucovorin can counteract the therapeutic and toxic effects of folic acid; antagonists such as methotrexate, which act by inhibiting dihydrofolate reductase.; 12.1.2 Levoleucovorin effects in combination with 5-fluorouracil; Levoleucovorin can enhance the therapeutic and toxic effects of fluoropyrimidines used in cancer therapy such as; 5-fluorouracil. 5-fluorouracil is metabolized to 5-fluoro-2'-deoxyuridine-5'-monophosphate (FdUMP), which binds to and; inhibits thymidylate synthase (an enzyme important in DNA repair and replication). Levoleucovorin is readily converted; to another reduced folate, 5,10-methylenetetrahydrofolate, which acts to stabilize the binding of FdUMP to thymidylate; synthase and thereby enhances the inhibition of this enzyme.
Stivarga13 38 REGORAFENIB Bayer/ Bayer HealthCare Pharmaceuticals Approved February 2013/ Approved September 2012
FDA Label: Stivarga
Malady that Drug Treats: gastrointestinal stromal tumor/ metastatic colorectal cancer
Indications and Usage:13 Stivarga is a kinase inhibitor indicated for the treatment of patients with:; Metastatic colorectal cancer (CRC) who have been previously treated with; fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an antiVEGF; therapy, and, if KRAS wild type, an anti-EGFR therapy. (1.1); Locally advanced, unresectable or metastatic gastrointestinal stromal tumor; (GIST) who have been previously treated with imatinib mesylate and; sunitinib malate. (1.2)
DrugBank Targets:11 1. Proto-oncogene tyrosine-protein kinase receptor Ret; 2. Vascular endothelial growth factor receptor 1; 3. Vascular endothelial growth factor receptor 2; 4. Vascular endothelial growth factor receptor 3; 5. Mast/stem cell growth factor receptor Kit; 6. Platelet-derived growth factor receptor alpha; 7. Platelet-derived growth factor receptor beta; 8. Fibroblast growth factor receptor 1; 9. Fibroblast growth factor receptor 2; 10. Angiopoietin-1 receptor; 11. Discoidin domain-containing receptor 2; 12. High affinity nerve growth factor receptor; 13. Ephrin type-A receptor 2; 14. RAF proto-oncogene serine/threonine-protein kinase; 15. Serine/threonine-protein kinase B-raf; 16. Mitogen-activated protein kinase 11; 17. Tyrosine-protein kinase FRK; 18. Tyrosine-protein kinase ABL1
Mechanism of Action:13 
Target: RET, VEGFR1, VEGFR2, VEGFR3, KIT, PDGFR-alpha, PDGFR-beta, FGFR1, FGFR2,; TIE2, DDR2, TrkA, Eph2A, RAF-1, BRAF, BRAFV600E , SAPK2, PTK5, and Abl kinases
Action: inhibitor
FDA: Regorafenib is a small molecule inhibitor of multiple membrane-bound and intracellular kinases involved in normal; cellular functions and in pathologic processes such as oncogenesis, tumor angiogenesis, and maintenance of the tumor; microenvironment. In in vitro biochemical or cellular assays, regorafenib or its major human active metabolites M-2 and; M-5 inhibited the activity of RET, VEGFR1, VEGFR2, VEGFR3, KIT, PDGFR-alpha, PDGFR-beta, FGFR1, FGFR2,; TIE2, DDR2, TrkA, Eph2A, RAF-1, BRAF, BRAFV600E , SAPK2, PTK5, and Abl at concentrations of regorafenib that; have been achieved clinically. In in vivo models, regorafenib demonstrated anti-angiogenic activity in a rat tumor model,; and inhibition of tumor growth as well as anti-metastatic activity in several mouse xenograft models including some for; human colorectal carcinoma.
Sutent13 38 SUNITINIB MALATE Pfizer Approved May 2011/ Approved January 2006
FDA Label: Sutent
Malady that Drug Treats: pancreatic neuroendocrine tumors/ Kidney Cancer/Gastrointestinal Stromal Tumors
Indications and Usage:13 SUTENT is a kinase inhibitor indicated for the treatment of:; Gastrointestinal stromal tumor (GIST) after disease progression on or; intolerance to imatinib mesylate. (1.1); Advanced renal cell carcinoma (RCC). (1.2); Progressive, well-differentiated pancreatic neuroendocrine tumors; (pNET) in patients with unresectable locally advanced or metastatic; disease. (1.3)
DrugBank Targets:11 1. Platelet-derived growth factor receptor beta; 2. Vascular endothelial growth factor receptor 1; 3. Mast/stem cell growth factor receptor Kit; 4. Vascular endothelial growth factor receptor 2; 5. Vascular endothelial growth factor receptor 3; 6. Receptor-type tyrosine-protein kinase FLT3; 7. Macrophage colony-stimulating factor 1 receptor; 8. Platelet-derived growth factor receptor alpha
Mechanism of Action:13 
Target: variety of kinases, platelet-derived growth factor receptors (PDGFR± and PDGFR²), vascular endothelial growth factor; receptors (VEGFR1, VEGFR2 and VEGFR3), stem cell factor receptor (KIT), Fms-like tyrosine kinase-3; (FLT3), colony stimulating factor receptor Type 1 (CSF-1R), and the glial cell-line derived neurotrophic factor; receptor (RET)
Action: inhibitor
FDA: Sunitinib is a small molecule that inhibits multiple receptor tyrosine kinases (RTKs), some of which are; implicated in tumor growth, pathologic angiogenesis, and metastatic progression of cancer. Sunitinib was; evaluated for its inhibitory activity against a variety of kinases (>80 kinases) and was identified as an inhibitor; of platelet-derived growth factor receptors (PDGFR± and PDGFR²), vascular endothelial growth factor; receptors (VEGFR1, VEGFR2 and VEGFR3), stem cell factor receptor (KIT), Fms-like tyrosine kinase-3; (FLT3), colony stimulating factor receptor Type 1 (CSF-1R), and the glial cell-line derived neurotrophic factor; receptor (RET). Sunitinib inhibition of the activity of these RTKs has been demonstrated in biochemical and; cellular assays, and inhibition of function has been demonstrated in cell proliferation assays. The primary; metabolite exhibits similar potency compared to sunitinib in biochemical and cellular assays.; Sunitinib inhibited the phosphorylation of multiple RTKs (PDGFRbð, VEGFR2, KIT) in tumor xenografts; expressing RTK targets in vivo and demonstrated inhibition of tumor growth or tumor regression and/or; inhibited metastases in some experimental models of cancer. Sunitinib demonstrated the ability to inhibit; growth of tumor cells expressing dysregulated target RTKs (PDGFR, RET, or KIT) in vitro and to inhibit; PDGFRbð- and VEGFR2-dependent tumor angiogenesis in vivo.
Vectibix13 38 PANITUMUMAB Amgen Approved September 2006
FDA Label: Vectibix
Malady that Drug Treats: colorectal cancer
Indications and Usage:13 Vectibix is an epidermal growth factor receptor (EGFR) antagonist indicated; for the treatment of wild-type KRAS (exon 2) metastatic colorectal cancer; (mCRC) as determined by an FDA-approved test for this use:; In combination with FOLFOX for first-line treatment. (1.1, 14.2); As monotherapy following disease progression after prior treatment with; fluoropyrimidine, oxaliplatin, and irinotecan-containing chemotherapy.; (1.1, 14.1); Limitation of Use: Vectibix is not indicated for the treatment of patients; with RAS-mutant mCRC or for whom RAS mutation status is unknown.; (1.1, 2.1, 5.2, 12.1)
DrugBank Targets:11 1. Epidermal growth factor receptor
Mechanism of Action:13 
Target: EGFR
Action: inhibitor of ligand binding
FDA: The EGFR is a transmembrane glycoprotein that is a member of a subfamily of type I receptor tyrosine kinases,; including EGFR, HER2, HER3, and HER4. EGFR is constitutively expressed in normal epithelial tissues,; including the skin and hair follicle. EGFR is overexpressed in certain human cancers, including colon and rectum; cancers. Interaction of EGFR with its normal ligands (eg, EGF, transforming growth factor-alpha) leads to; phosphorylation and activation of a series of intracellular proteins, which in turn regulate transcription of genes; involved with cellular growth and survival, motility, and proliferation. KRAS (Kirsten rat sarcoma 2 viral; oncogene homologue) and NRAS (Neuroblastoma RAS viral oncogene homologue) are highly related members of; the RAS oncogene family. Signal transduction through the EGFR can result in activation of the wild-type KRAS; and NRAS proteins; however, in cells with activating RAS somatic mutations, the RAS-mutant proteins are; continuously active and appear independent of EGFR regulation.; Panitumumab binds specifically to EGFR on both normal and tumor cells, and competitively inhibits the binding; of ligands for EGFR. Nonclinical studies show that binding of panitumumab to the EGFR prevents ligand-induced; receptor autophosphorylation and activation of receptor-associated kinases, resulting in inhibition of cell growth,; induction of apoptosis, decreased proinflammatory cytokine and vascular growth factor production, and; internalization of the EGFR. In vitro assays and in vivo animal studies demonstrate that panitumumab inhibits the; growth and survival of selected human tumor cell lines expressing EGFR.
Xeloda13 38 CAPECITABINE Roche Approved April 1998/ Approved May 2001
FDA Label: Xeloda
Malady that Drug Treats: breast cancer/ metastatic colorectal cancer
Indications and Usage:13 XELODA (capecitabine) is a nucleoside metabolic inhibitor with; antineoplastic activity indicated for:; Adjuv ant Colon Cancer (1.1); - Patients with Dukes C colon cancer; Metastatic Colorectal Cancer (1.1); - First-line as monotherapy when treatment with fluoropyrimidine; therapy alone is preferred; Metastatic Breast Cancer (1.2); - In combination with docetaxel after failure of prior anthracyclinecontaining; therapy; - As monotherapy in patients resistant to both paclitaxel and an; anthracycline-containing regimen
DrugBank Targets:11 1. Thymidylate synthase; 2. DNA; 3. RNA
Mechanism of Action:13 
Target: capecitabine
Action: converted to 5-fluorouracil (5-FU) --> cause cell injury
FDA: Enzymes convert capecitabine to 5-fluorouracil (5-FU) in vivo. Both normal and tumor cells; metabolize 5-FU to 5-fluoro-2 -deoxyuridine monophosphate (FdUMP) and 5-fluorouridine; triphosphate (FUTP). These metabolites cause cell injury by two different mechanisms. First,; FdUMP and the folate cofactor, N5-10-methylenetetrahydrofolate, bind to thymidylate synthase; (TS) to form a covalently bound ternary complex. This binding inhibits the formation of; thymidylate from 2 -deoxyuridylate. Thymidylate is the necessary precursor of thymidine; triphosphate, which is essential for the synthesis of DNA, so that a deficiency of this compound; can inhibit cell division. Second, nuclear transcriptional enzymes can mistakenly incorporate; FUTP in place of uridine triphosphate (UTP) during the synthesis of RNA. This metabolic error; can interfere with RNA processing and protein synthesis.
Zaltrap13 38 ZIV-AFLIBERCEPT Sanofi-aventis Approved August 2012
FDA Label: Zaltrap
Malady that Drug Treats: metastatic colorectal cancer
Indications and Usage:13 ZALTRAP, in combination with 5-fluorouracil, leucovorin, irinotecan- ; (FOLFIRI), is indicated for patients with metastatic colorectal cancer (mCRC); that is resistant to or has progressed following an oxaliplatin-containing; regimen. (1)
DrugBank Targets:11 1. Vascular endothelial growth factor A; 2. Placenta growth factor; 3. Vascular endothelial growth factor B
Mechanism of Action:13 
Target: VEGF-A, VEGF-B, PlGF
Action: inhibitor of binding and activation of their cognate receptors
FDA: Ziv-aflibercept acts as a soluble receptor that binds to human VEGF-A (equilibrium dissociation; constant KD of 0.5 pM for VEGF-A165 and 0.36 pM for VEGF-A121), to human VEGF-B (KD of; 1.92 pM), and to human PlGF (KD of 39 pM for PlGF-2). By binding to these endogenous; ligands, ziv-aflibercept can inhibit the binding and activation of their cognate receptors. This; inhibition can result in decreased neovascularization and decreased vascular permeability.; In animals, ziv-aflibercept was shown to inhibit the proliferation of endothelial cells, thereby; inhibiting the growth of new blood vessels. Ziv-aflibercept inhibited the growth of; xenotransplanted colon tumors in mice.

Drug clinical trials:

Search ClinicalTrials for Colorectal Cancer

Search NIH Clinical Center for Colorectal Cancer

Inferred drug relations via UMLS61/NDF-RT40:

Genetic Tests for Colorectal Cancer

About this section

Genetic tests related to Colorectal Cancer:

id Genetic test Affiliating Genes
1 Colon Cancer (apc I1307k Related)20 APC
2 Carcinoma of Colon22

Anatomical Context for Colorectal Cancer

About this section

MalaCards organs/tissues related to Colorectal Cancer:

Colon, Liver, Breast, Endothelial, Testes, Lymph node, T cells, Skeletal muscle, Lung, Prostate, Bone, Brain, Testis, Myeloid, Bone marrow, Monocytes, Eye, Skin, Placenta, Adipocyte, Kidney, Whole blood, Neutrophil, Pancreas, Thyroid, Pituitary, Heart, Small intestine, Nk cells, B cells, Fetal liver, Appendix

FMA organs/tissues related to Colorectal Cancer:

The colon

Animal Models for Colorectal Cancer or affiliated genes

About this section

MGI Mouse Phenotypes related to Colorectal Cancer:

35 (show all 27)
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:001076812.6BRAF, FGFR3, AXIN2, CTNNB1, BAX, NRAS
2MP:000538412.5PIK3CA, BAX, CTNNB1, AXIN2, FGFR3, NRAS
3MP:000200612.3FGFR3, CTNNB1, NRAS, CCND1, AKT1, EP300
4MP:000537812.2BRAF, TP53, APC, FLCN, BUB1B, PTPRJ
5MP:000538012.2APC, AURKA, AXIN2, CTNNB1, NRAS, AKT1
7MP:000537612.1FLCN, BRAF, TP53, APC, BUB1B, FGFR3
8MP:000539112.1TP53, FGFR3, DCC, AXIN2, CTNNB1, NRAS
9MP:000538912.1FGFR3, PIK3CA, MLH3, PTPRJ, BUB1B, APC
10MP:000538512.0AXIN2, CTNNB1, CCND1, AKT1, PIK3CA, EP300
11MP:000539712.0AKT1, FGFR3, CTNNB1, BUB1B, APC, TP53
12MP:000363111.8CCND1, FGFR3, PIK3CA, TP53, DCC, BRAF
13MP:000287311.8NRAS, PTPRJ, ODC1, APC, BRAF, CCND1
14MP:000538811.7FGFR3, EP300, PTPRJ, CTNNB1, BAX, CCND1
15MP:000536911.7EP300, BRAF, TP53, BUB1B, PIK3CA, AKT1
16MP:000537911.7TP53, BAX, PIK3CA, CTNNB1, CCND1, AKT1
17MP:000539011.7AXIN2, CTNNB1, BAX, CCND1, AKT1, FGFR3
18MP:001077111.7BUB1B, NRAS, CCND1, CTNNB1, FGFR3, AKT1
19MP:000538611.6APC, BUB1B, PIK3CA, FGFR3, TP53, DCC
20MP:000538211.6AXIN2, CCND1, CTNNB1, FGFR3, PTPRJ, APC
21MP:000301211.5NRAS, PIK3CA, AURKA, PTPRJ, APC, TP53
22MP:000538111.5CTNNB1, FGFR3, EP300, BRAF, DCC, TP53
23MP:000536711.3APC, EP300, FGFR3, TP53, BRAF, FLCN
24MP:000537111.1FGFR3, APC, TP53, NRAS, BAX, CTNNB1
25MP:000537011.0PTPRJ, NRAS, AKT1, BRAF, TP53, APC
26MP:000118611.0CTNNB1, BRAF, DCC, TP53, APC
27MP:000537510.8BUB1B, PIK3CA, AKT1, BRAF, TP53, APC

Publications for Colorectal Cancer

About this section

Articles related to Colorectal Cancer:

(show top 50)    (show all 7820)
The effect of oxoguanine glycosylase 1 rs1052133 polymorphism on colorectal cancer risk in Caucasian population. (23975367)
E2A suppresses invasion and migration by targeting YAP in colorectal cancer cells. (24369055)
Reduced FHIT expression is associated with mismatch repair deficient and high CpG island methylator phenotype colorectal cancer. (23797051)
Adherence With Postdischarge Venous Thromboembolism Chemoprophylaxis Recommendations After Colorectal Cancer Surgery Among Elderly Medicare Beneficiaries. (24169191)
Metachronous colorectal cancer: A competing risks analysis with consideration for a stratified approach to surveillance colonoscopy. (24272767)
Detection of lymph node metastases in human colorectal cancer by using 5-aminolevulinic acid-induced protoporphyrin IX fluorescence with spectral unmixing. (24284403)
Survival after inflammatory bowel disease-associated colorectal cancer in the Colon Cancer Family Registry. (23745025)
Subclinical peripheral neuropathy is a common finding in colorectal cancer patients prior to chemotherapy. (22496202)
Oxidative stress induces nuclear-to-cytosol shift of hMSH3, a potential mechanism for EMAST in colorectal cancer cells. (23226332)
Signal transduction pathways of the epidermal growth factor receptor in colorectal cancer and their inhibition by small molecules. (23033949)
Lymph node tissue kallikrein-related peptidase 6 mRNA: a progression marker for colorectal cancer. (22699826)
Proximal fluid proteome profiling of mouse colon tumors reveals biomarkers for early diagnosis of human colorectal cancer. (22351690)
Resistance of colorectal cancer cells to radiation and 5-FU is associated with MELK expression. (21806965)
Increased colorectal cancer risk in first-degree relatives of patients with hyperplastic polyposis syndrome. (20584785)
BRAF mutation predicts resistance to anti-EGFR monoclonal antibodies in wild-type KRAS metastatic colorectal cancer. (20514492)
High frequency of tumor-infiltrating FOXP3(+) regulatory T cells predicts improved survival in mismatch repair-proficient colorectal cancer patients. (19856313)
A small-molecule metastasis inhibitor, norcantharidin, downregulates matrix metalloproteinase-9 expression by inhibiting Sp1 transcriptional activity in colorectal cancer cells. (19616522)
Individualized therapies in colorectal cancer: KRAS as a marker for response to EGFR-targeted therapy. (19386128)
P53 and EGFR expression in colorectal cancer: a reappraisal of 'old' tissue markers in patients with long follow-up. (19331236)
Invasion front-specific overexpression of tissue inhibitor of metalloproteinase-1 in liver metastases from colorectal cancer. (18630499)
An open-label, single-arm study assessing safety and efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapy. (17785764)
KRAS mutation in metastatic colorectal cancer and its impact on the use of EGFR inhibitors. (19378369)
Trichostatin A causes p53 to switch oxidative-damaged colorectal cancer cells from cell cycle arrest into apoptosis. (18419600)
Curcumin sensitizes human colorectal cancer xenografts in nude mice to gamma-radiation by targeting nuclear factor-kappaB-regulated gene products. (18381954)
Galectin-3 expression in colorectal cancer: relation to invasion and metastasis. (17695516)
Peroxisome proliferator-activated receptor gamma: a common link for non-alcoholic fatty liver disease and colorectal cancer? (17482764)
Genetic testing in colorectal cancer: who, when, how and why. (17392593)
CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. (16804544)
Nuclear expression of thymidylate synthase in colorectal cancer cell lines and clinical samples. (15956025)
Expression of maspin in colorectal cancer. (17203770)
Relationships between the expressions of CDX1 and CDX2 mRNA and clinicopathologic features in colorectal cancers. (16491830)
Characterization of p53 wild-type and null isogenic colorectal cancer cell lines resistant to 5-fluorouracil, oxaliplatin, and irinotecan. (15041737)
High expression of PRL-3 promotes cancer cell motility and liver metastasis in human colorectal cancer: a predictive molecular marker of metachronous liver and lung metastases. (15534108)
The role of new agents in the treatment of colorectal cancer. (15031593)
First-line treatment of metastatic colorectal cancer with irinotecan, oxaliplatin and 5-fluorouracil/leucovorin (FOLFOXIRI): results of a phase II study with a simplified biweekly schedule. (15550581)
Thymidylate synthase gene polymorphism predicts toxicity in colorectal cancer patients receiving 5-fluorouracil-based chemotherapy. (15355920)
Carrier risk status changes resulting from mutation testing in hereditary non-polyposis colorectal cancer and hereditary breast-ovarian cancer. (12920070)
Circulating vascular endothelial growth factor six months after primary surgery as a prognostic marker in patients with colorectal cancer. (14968945)
Significance of transforming growth factor beta1 as a new tumor marker for colorectal cancer. (11802214)
Enhanced 3-hydroxy-3-methyl-glutaryl coenzyme A reductase activity in human colorectal cancer not expressing low density lipoprotein receptor. (10226581)
Detection of cytokeratins 19/20 and guanylyl cyclase C in peripheral blood of colorectal cancer patients. (10206298)
CDX2 is mutated in a colorectal cancer with normal APC/beta-catenin signaling. (10490837)
Lack of PMS2 gene-truncating mutations in patients with hereditary colorectal cancer. (9683794)
Vascular endothelial growth factor expression is reduced in liver metastasis from colorectal cancer and correlates with urokinase-type plasminogen activator. (9615749)
Soluble CD44 and CD44v6 serum levels in patients with colorectal cancer are independent of tumor stage and tissue expression of CD44v6. (9625129)
Beta-catenin mutations in cell lines established from human colorectal cancers. (9294210)
Expression of alternatively spliced lck transcripts from the proximal promoter in colorectal cancer derived cell lines. (8712692)
APC mutation analysis in sporadic colorectal cancer]. (9387290)
Colonoscopy in relation to the evolving genetics of familial colorectal cancer. (7601034)
Mutational analysis of the hMSH2 gene reveals a three base pair deletion in a family predisposed to colorectal cancer development. (7874129)

Variations for Colorectal Cancer

About this section

UniProtKB/Swiss-Prot genetic disease variations for Colorectal Cancer:

63 (show all 17)
id Symbol AA change Variation ID SNP ID

Clinvar genetic disease variations for Colorectal Cancer:

5 (show all 13)
id Gene Variation Type Significance SNP ID Assembly Location
1TP53NM_000546.5(TP53): c.974G> T (p.Gly325Val)single nucleotide variantPathogenicrs121912659GRCh37Chr 17, 7576872: 7576872
2TP53NM_000546.5(TP53): c.566C> T (p.Ala189Val)single nucleotide variantPathogenicrs121912665GRCh37Chr 17, 7578283: 7578283
3PLA2G2ANM_000300.3(PLA2G2A): c.144_145delTG (p.Cys48Trpfs)deletionPathogenicGRCh37Chr 1, 20304913: 20304914
4PIK3CANM_006218.2(PIK3CA): c.3140A> G (p.His1047Arg)single nucleotide variantPathogenicrs121913279GRCh37Chr 3, 178952085: 178952085
5PIK3CANM_006218.2(PIK3CA): c.1633G> A (p.Glu545Lys)single nucleotide variantPathogenicrs104886003GRCh37Chr 3, 178936091: 178936091
6AKT1NM_001014431.1(AKT1): c.49G> A (p.Glu17Lys)single nucleotide variantPathogenicrs121434592GRCh37Chr 14, 105246551: 105246551
7MT-CO2m.8009G> Asingle nucleotide variantPathogenicrs199474826GRCh37Chr MT, 8009: 8009
8MT-CO1m.6264G> Asingle nucleotide variantPathogenicrs267606882GRCh37Chr MT, 6264: 6264
9MT-CO1m.6277G> Asingle nucleotide variantPathogenicGRCh37Chr MT, 6277: 6277
10MT-CO1m.7275T> Csingle nucleotide variantPathogenicGRCh37Chr MT, 7275: 7275
11MT-CYBm.14985G> Asingle nucleotide variantPathogenicrs207459995GRCh37Chr MT, 14985: 14985
12MT-CYBm.15572T> Csingle nucleotide variantPathogenicrs207459996GRCh37Chr MT, 15572: 15572
13MT-ND4Lm.10563T> Csingle nucleotide variantPathogenicrs267606892GRCh37Chr MT, 10563: 10563

Cosmic variations for Colorectal Cancer:

id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
1532KRASlarge intestine,colon,other,ulcerative colitis3
2528KRASlarge intestine,colon,other,ulcerative colitis3
3516KRASlarge intestine,colon,other,ulcerative colitis3
4520KRASlarge intestine,colon,other,ulcerative colitis3
5521KRASlarge intestine,colon,other,ulcerative colitis3

Expression for genes affiliated with Colorectal Cancer

About this section
LifeMap Discovery
Genes differentially expressed in tissues of Colorectal Cancer patients vs. healthy controls: 30 (show all 291)
id Gene Description Tissue Up/Dn Fold Change (log2) P value
2GUCA2Bguanylate cyclase activator 2B (uroguanylin)Colon-8.780.000
3MS4A12membrane-spanning 4-domains, subfamily A, member 12Colon-8.780.000
4AQP8aquaporin 8Colon-8.300.000
5CA1carbonic anhydrase IColon-8.110.000
6CLCA4chloride channel accessory 4Colon-7.630.000
7CA4carbonic anhydrase IVColon-7.510.000
8TCN1transcobalamin I (vitamin B12 binding protein, R binder family)Colon+7.340.000
9CLDN8claudin 8Colon-7.180.000
10CDH3cadherin 3, type 1, P-cadherin (placental)Colon+6.970.000
11GUCA2Aguanylate cyclase activator 2A (guanylin)Colon-6.920.000
12HLA-DQB1major histocompatibility complex, class II, DQ beta 1Colon-6.850.001
13PRAC1prostate cancer susceptibility candidate 1Colon-6.720.040
14CEMIPcell migration inducing protein, hyaluronan bindingColon+6.690.000
15INSL5insulin-like 5Colon-6.670.000
16PYYpeptide YYColon-6.570.000
17SCNN1Bsodium channel, non-voltage-gated 1, beta subunitColon-6.530.000
18CHGAchromogranin A (parathyroid secretory protein 1)Colon-6.300.000
19CDH3cadherin 3, type 1, P-cadherin (placental)Colon+6.140.000
21ABCG2ATP-binding cassette, sub-family G (WHITE), member 2Colon-5.770.002
22HCAR3hydroxycarboxylic acid receptor 3Colon+5.600.000
23INHBAinhibin, beta AColon+5.560.000
24SLC51Bsolute carrier family 51, beta subunitColon-5.540.001
25CD177CD177 moleculeColon-5.520.003
26GCNT2glucosaminyl (N-acetyl) transferase 2, I-branching enzyme (I blood group)Colon-5.480.000
27SLC25A34solute carrier family 25, member 34Colon-5.430.000
28FBLN1fibulin 1Kidney-5.420.000
29SLC26A3solute carrier family 26 (anion exchanger), member 3Colon-5.390.002
30CDKN2Bcyclin-dependent kinase inhibitor 2B (p15, inhibits CDK4)Colon-5.350.000
31ZG16zymogen granule protein 16Colon-5.340.000
32MSX2msh homeobox 2Colon+5.310.000
33FABP6fatty acid binding protein 6, ilealColon+5.290.000
34IL8interleukin 8Colon+5.260.000
35EPHX4epoxide hydrolase 4Colon+5.240.000
36DUSP27dual specificity phosphatase 27 (putative)Colon+5.230.000
37TACSTD2tumor-associated calcium signal transducer 2Colon+5.100.000
38GABRPgamma-aminobutyric acid (GABA) A receptor, piColon+5.080.003
39BEST4bestrophin 4Colon-5.080.001
40S100A2S100 calcium binding protein A2Colon+5.050.000
41DPEP1dipeptidase 1 (renal)Colon+5.040.010
42MUC12mucin 12, cell surface associatedColon-4.980.020
43SPINK5serine peptidase inhibitor, Kazal type 5Colon-4.960.001
44PCSK1proprotein convertase subtilisin/kexin type 1Colon+4.920.008
45SLC30A10solute carrier family 30, member 10Colon-4.890.003
46TMEM72transmembrane protein 72Colon-4.880.000
47KLK10kallikrein-related peptidase 10Colon+4.850.020
48COL12A1collagen, type XII, alpha 1Colon+4.840.000
49CDH19cadherin 19, type 2Colon-4.830.001
50CDKN2B-AS1CDKN2B antisense RNA 1Colon-4.750.004
51MT1Mmetallothionein 1MColon-4.750.027
52SLC6A19solute carrier family 6 (neutral amino acid transporter), member 19Colon-4.710.007
53PCK1phosphoenolpyruvate carboxykinase 1 (soluble)Colon-4.700.000
54ANO5anoctamin 5Colon-4.680.000
55CEMIPcell migration inducing protein, hyaluronan bindingColon+4.630.008
56FOXQ1forkhead box Q1Colon+4.620.000
57CEACAM7carcinoembryonic antigen-related cell adhesion molecule 7Colon-4.600.001
58MMP7matrix metallopeptidase 7 (matrilysin, uterine)Colon+4.590.003
59TEX11testis expressed 11Colon-4.560.000
60ABCA8ATP-binding cassette, sub-family A (ABC1), member 8Colon-4.550.000
61KRT6Bkeratin 6BColon+4.550.006
62SLC22A3solute carrier family 22 (organic cation transporter), member 3Colon+4.550.001
63C2CD4AC2 calcium-dependent domain containing 4AColon+4.540.000
64CRNDEcolorectal neoplasia differentially expressed (non-protein coding)Colon+4.530.000
65CA2carbonic anhydrase IIColon-4.530.001
66CCL8chemokine (C-C motif) ligand 8Colon-4.510.000
67NEUROD1neuronal differentiation 1Colon-4.490.001
68ALPIalkaline phosphatase, intestinalColon-4.480.000
69INHBAinhibin, beta AColon+4.470.001
72COL12A1collagen, type XII, alpha 1Colon+4.410.000
73L1TD1LINE-1 type transposase domain containing 1Colon+4.410.004
74SLC15A1solute carrier family 15 (oligopeptide transporter), member 1Colon-4.410.006
75C21orf88chromosome 21 open reading frame 88Colon-4.410.004
76ACHEacetylcholinesterase (Yt blood group)Colon-4.390.000
77NPWneuropeptide WColon+4.390.035
78EPB41L3erythrocyte membrane protein band 4.1-like 3Colon-4.380.009
79SLC35D3solute carrier family 35, member D3Colon+4.370.007
80CRYBA2crystallin, beta A2Colon-4.370.000
81GREM1gremlin 1, DAN family BMP antagonistColon+4.370.002
82VSTM2AV-set and transmembrane domain containing 2AColon-4.360.008
83LOC100289026putative uncharacterized protein FLJ00310-likeColon+4.320.012
84MUC5ACmucin 5AC, oligomeric mucus/gel-formingColon+4.310.019
85RBM24RNA binding motif protein 24Colon-4.310.011
86SH3TC2SH3 domain and tetratricopeptide repeats 2Colon+4.290.000
87WDR72WD repeat domain 72Colon+4.280.005
88SLC4A4solute carrier family 4 (sodium bicarbonate cotransporter), member 4Colon-4.260.002
90DPP4dipeptidyl-peptidase 4Colon-4.210.002
91SLC16A4solute carrier family 16, member 4Colon+4.160.001
92CA7carbonic anhydrase VIIColon-4.160.001
93XKR4XK, Kell blood group complex subunit-related family, member 4Colon-4.160.000
94EDN3endothelin 3Colon-4.150.000
95LGALS2lectin, galactoside-binding, soluble, 2Colon-4.140.001
96DHRS9dehydrogenase/reductase (SDR family) member 9Colon-4.130.004
97PKIBprotein kinase (cAMP-dependent, catalytic) inhibitor betaColon-4.110.001
98ENPP6ectonucleotide pyrophosphatase/phosphodiesterase 6Colon-4.110.005
99DSG3desmoglein 3Colon+4.110.003
100FAM3Bfamily with sequence similarity 3, member BColon+4.100.023
101IL20RAinterleukin 20 receptor, alphaColon+4.090.009
102DPP10dipeptidyl-peptidase 10 (non-functional)Colon-4.080.000
103UGT2A3UDP glucuronosyltransferase 2 family, polypeptide A3Colon-4.080.003
104STC2stanniocalcin 2Colon+4.070.006
105DPEP2dipeptidase 2Colon-4.060.000
106PLP1proteolipid protein 1Colon-4.050.009
107ANPEPalanyl (membrane) aminopeptidaseColon-4.050.003
108LOC254057uncharacterized LOC254057Colon+4.050.001
109ETV4ets variant 4Colon+4.040.000
110CXCL12chemokine (C-X-C motif) ligand 12Colon-4.030.022
111RETNLBresistin like betaColon+4.030.039
112SUGCTsuccinylCoA:glutarate-CoA transferaseColon-4.030.006
113SIsucrase-isomaltase (alpha-glucosidase)Colon-4.010.028
114NRXN1neurexin 1Colon-4.010.013
115SP5Sp5 transcription factorColon+3.990.001
116WSCD1WSC domain containing 1Colon-3.980.030
117CXCL5chemokine (C-X-C motif) ligand 5Colon+3.970.004
118SCG2secretogranin IIColon-3.970.012
119KRT23keratin 23 (histone deacetylase inducible)Colon+3.960.017
120CR2complement component (3d/Epstein Barr virus) receptor 2Colon-3.950.003
121FABP4fatty acid binding protein 4, adipocyteColon-3.950.008
122UBE2QL1ubiquitin-conjugating enzyme E2Q family-like 1Colon-3.930.000
123SERPINB5serpin peptidase inhibitor, clade B (ovalbumin), member 5Colon+3.930.003
124AMPD1adenosine monophosphate deaminase 1Colon-3.930.023
125FGFBP2fibroblast growth factor binding protein 2Colon-3.930.000
126SCGNsecretagogin, EF-hand calcium binding proteinColon-3.930.001
127EYA2eyes absent homolog 2 (Drosophila)Colon-3.920.029
128SLC26A2solute carrier family 26 (anion exchanger), member 2Colon-3.880.000
129DPEP1dipeptidase 1 (renal)Colon+3.880.039
130TMCO5Btransmembrane and coiled-coil domains 5B, pseudogeneColon-3.880.000
131PNLIPRP2pancreatic lipase-related protein 2Colon-3.880.042
133CNKSR2connector enhancer of kinase suppressor of Ras 2Colon-3.870.021
134MALLmal, T-cell differentiation protein-likeColon-3.870.000
135MFAP4microfibrillar-associated protein 4Colon-3.860.004
136COL11A1collagen, type XI, alpha 1Colon+3.860.007
137CDC14Ccell division cycle 14CColon-3.850.008
138TDRD5tudor domain containing 5Colon+3.840.004
139BRINP3bone morphogenetic protein/retinoic acid inducible neural-specific 3Colon-3.840.012
140ANGPTL1angiopoietin-like 1Colon-3.840.037
141TAC1tachykinin, precursor 1Colon+3.830.031
142IL33interleukin 33Colon+3.810.003
143KCNQ5potassium voltage-gated channel, KQT-like subfamily, member 5Colon-3.810.002
144S100A2S100 calcium binding protein A2Colon+3.800.013
145KRT80keratin 80Colon+3.800.001
146LGI4leucine-rich repeat LGI family, member 4Colon-3.790.000
147MST1Lmacrophage stimulating 1-likeColon-3.790.021
148ITPKAinositol-trisphosphate 3-kinase AColon-3.790.011
149LPLlipoprotein lipaseColon+3.780.003
150CLDN2claudin 2Colon+3.770.002
151GRIA3glutamate receptor, ionotropic, AMPA 3Colon-3.760.025
152MFSD4major facilitator superfamily domain containing 4Colon-3.750.039
153CYP4X1cytochrome P450, family 4, subfamily X, polypeptide 1Colon+3.750.001
154CPMcarboxypeptidase MColon-3.750.011
155KRT6Bkeratin 6BColon+3.730.002
156KRT23keratin 23 (histone deacetylase inducible)Colon+3.730.004
157SBSPONsomatomedin B and thrombospondin, type 1 domain containingColon+3.720.002
158GPM6Bglycoprotein M6BColon-3.720.000
159SCNN1Gsodium channel, non-voltage-gated 1, gamma subunitColon-3.720.019
160UNC5Cunc-5 homolog C (C. elegans)Colon-3.710.016
161SCN7Asodium channel, voltage-gated, type VII, alpha subunitColon-3.700.001
162ZNF229zinc finger protein 229Colon-3.670.001
163GIFgastric intrinsic factor (vitamin B synthesis)Colon+3.670.002
164LRRN1leucine rich repeat neuronal 1Colon+3.670.015
165FMN2formin 2Colon-3.670.016
166OSR1odd-skipped related transciption factor 1Colon-3.660.000
167GALNT6polypeptide N-acetylgalactosaminyltransferase 6Colon+3.660.004
168LAMA4laminin, alpha 4Colon-3.660.007
169ASCL2achaete-scute family bHLH transcription factor 2Colon+3.650.009
170SERPINA6serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 6Colon-3.650.009
171OLFM1olfactomedin 1Colon-3.640.001
172ADH1Balcohol dehydrogenase 1B (class I), beta polypeptideColon-3.640.039
173NR5A2nuclear receptor subfamily 5, group A, member 2Colon-3.640.049
174SLC28A3solute carrier family 28 (concentrative nucleoside transporter), member 3Colon+3.630.001
175NAALADL1N-acetylated alpha-linked acidic dipeptidase-like 1Colon-3.630.000
176SV2Bsynaptic vesicle glycoprotein 2BColon-3.630.000
177MMP3matrix metallopeptidase 3 (stromelysin 1, progelatinase)Colon+3.630.044
178FXYD1FXYD domain containing ion transport regulator 1Colon-3.630.003
179TNS4tensin 4Colon+3.620.002
180CDH12cadherin 12, type 2 (N-cadherin 2)Colon-3.620.003
181HRCT1histidine rich carboxyl terminus 1Colon-3.620.000
182HLA-DQA1major histocompatibility complex, class II, DQ alpha 1Colon-3.620.038
183DOCK10dedicator of cytokinesis 10Colon-3.600.026
184ADAMDEC1ADAM-like, decysin 1Colon-3.600.000
185SIGLEC1sialic acid binding Ig-like lectin 1, sialoadhesinColon-3.600.004
186HSD17B2hydroxysteroid (17-beta) dehydrogenase 2Colon-3.600.006
187KLHL32kelch-like family member 32Colon+3.590.007
188CLDN23claudin 23Colon-3.590.000
189PIK3R5phosphoinositide-3-kinase, regulatory subunit 5Colon-3.590.001
190SPIBSpi-B transcription factor (Spi-1/PU.1 related)Colon-3.570.004
191RNF165ring finger protein 165Colon-3.560.001
192DLX6-AS1DLX6 antisense RNA 1Colon+3.550.015
193SIM2single-minded family bHLH transcription factor 2Colon+3.540.004
194CCL18chemokine (C-C motif) ligand 18 (pulmonary and activation-regulated)Colon-3.540.031
195C11orf86chromosome 11 open reading frame 86Colon-3.520.000
196LRRC8Eleucine rich repeat containing 8 family, member EColon+3.520.001
197USP2ubiquitin specific peptidase 2Colon-3.520.005
198TRPM6transient receptor potential cation channel, subfamily M, member 6Colon-3.520.001
199GLS2glutaminase 2 (liver, mitochondrial)Colon+3.500.000
200DUSP4dual specificity phosphatase 4Colon+3.500.015
201LGR5leucine-rich repeat containing G protein-coupled receptor 5Colon+3.500.012
202TTLL6tubulin tyrosine ligase-like family, member 6Colon-3.490.021
203ZNF605zinc finger protein 605Colon-3.490.007
204SLCO2B1solute carrier organic anion transporter family, member 2B1Colon-3.480.005
205CXCL13chemokine (C-X-C motif) ligand 13Colon-3.470.037
206SEMA6Dsema domain, transmembrane domain (TM), and cytoplasmic domain, (semaphorin) 6DColon-3.470.025
207FLJ36848uncharacterized LOC647115Colon-3.470.005
208EPHA3EPH receptor A3Colon-3.460.017
209ATF7IPactivating transcription factor 7 interacting proteinColon+3.460.025
210CDHR5cadherin-related family member 5Colon-3.460.000
211MMP10matrix metallopeptidase 10 (stromelysin 2)Colon+3.460.023
213ZDHHC2zinc finger, DHHC-type containing 2Colon+3.450.000
214AXIN2axin 2Colon+3.440.001
215SPINK4serine peptidase inhibitor, Kazal type 4Colon+3.440.000
216INSM1insulinoma-associated 1Colon-3.440.018
217DNAH14dynein, axonemal, heavy chain 14Colon+3.440.000
218SPON1spondin 1, extracellular matrix proteinColon-3.440.000
219HPGDhydroxyprostaglandin dehydrogenase 15-(NAD)Colon-3.430.000
220TRDT cell receptor delta locusColon-3.430.001
221C11orf65chromosome 11 open reading frame 65Colon+3.430.000
222GRIN2Dglutamate receptor, ionotropic, N-methyl D-aspartate 2DColon+3.430.001
223ASB2ankyrin repeat and SOCS box containing 2Colon-3.430.007
224STMN2stathmin 2Colon-3.420.009
225KLK11kallikrein-related peptidase 11Colon+3.420.001
226NAP1L2nucleosome assembly protein 1-like 2Colon-3.420.004
227TCF21transcription factor 21Colon-3.420.001
228IGHA1immunoglobulin heavy constant alpha 1Colon-3.420.003
229LCN2lipocalin 2Colon+3.420.003
230POSTNperiostin, osteoblast specific factorColon-3.420.000
231FCRL2Fc receptor-like 2Colon-3.410.000
232KRT78keratin 78Colon-3.410.002
233HERC6HECT and RLD domain containing E3 ubiquitin protein ligase family member 6Colon-3.410.019
234CYTL1cytokine-like 1Colon-3.410.011
235CHP2calcineurin-like EF-hand protein 2Colon-3.410.004
236LOC401463uncharacterized LOC401463Colon-3.410.013
237IGLV1-36immunoglobulin lambda variable 1-36Colon-3.400.020
238SIGLEC6sialic acid binding Ig-like lectin 6Colon-3.390.002
239CHRM3cholinergic receptor, muscarinic 3Colon+3.390.031
240TSPAN5tetraspanin 5Colon+3.390.004
241REG4regenerating islet-derived family, member 4Colon+3.380.001
242VSTM4V-set and transmembrane domain containing 4Colon-3.380.011
243C2orf88chromosome 2 open reading frame 88Colon-3.380.000
244GGT5gamma-glutamyltransferase 5Colon-3.380.006
245PIANPPILR alpha associated neural proteinColon-3.370.001
246COL11A1collagen, type XI, alpha 1Colon+3.360.001
247HOXC6homeobox C6Colon+3.360.017
248PDE3Aphosphodiesterase 3A, cGMP-inhibitedColon-3.360.001
249FAM150Bfamily with sequence similarity 150, member BColon-3.360.008
250SOSTDC1sclerostin domain containing 1Colon-3.350.000
251PLAC9placenta-specific 9Colon-3.350.006
252CDRT1CMT1A duplicated region transcript 1Colon-3.350.002
253GPR55G protein-coupled receptor 55Colon-3.350.004
254SORCS1sortilin-related VPS10 domain containing receptor 1Colon-3.340.024
255MSX1msh homeobox 1Colon+3.340.002
256CPNE8copine VIIIColon-3.340.009
257MFAP5microfibrillar associated protein 5Colon-3.340.024
258BAI3brain-specific angiogenesis inhibitor 3Colon-3.330.030
260TAF13TAF13 RNA polymerase II, TATA box binding protein (TBP)-associated factor, 18kDaColon-3.320.004
261PPP1R10protein phosphatase 1, regulatory subunit 10Blood+3.310.000
262XKRXXK, Kell blood group complex subunit-related, X-linkedColon+3.300.000
263CRNDEcolorectal neoplasia differentially expressed (non-protein coding)Colon+3.300.013
264CHI3L1chitinase 3-like 1 (cartilage glycoprotein-39)Colon+3.290.003
265CHDHcholine dehydrogenaseColon+3.280.012
266MUC5ACmucin 5AC, oligomeric mucus/gel-formingColon+3.280.044
267TMEFF2transmembrane protein with EGF-like and two follistatin-like domains 2Colon+3.270.009
268FAIM2Fas apoptotic inhibitory molecule 2Colon+3.270.003
269DUSP18dual specificity phosphatase 18Colon+3.270.001
270CYP39A1cytochrome P450, family 39, subfamily A, polypeptide 1Colon+3.260.031
271MTRF1mitochondrial translational release factor 1Colon+3.250.006
272TBX3T-box 3Colon+3.230.004
273CCDC3coiled-coil domain containing 3Colon+3.220.022
274CADPSCa++-dependent secretion activatorColon+3.140.003
275TUBB1tubulin, beta 1 class VIColon+3.140.002
276MCM10minichromosome maintenance complex component 10Colon+3.140.001
277KRT80keratin 80Colon+3.130.016
278CHDHcholine dehydrogenaseColon+3.130.049
279RECQL5RecQ protein-like 5Colon+3.110.007
280ARNTL2aryl hydrocarbon receptor nuclear translocator-like 2Colon+3.110.007
281DUOX2dual oxidase 2Colon+3.100.018
282IL17Finterleukin 17FColon+3.100.000
283MMP7matrix metallopeptidase 7 (matrilysin, uterine)Colon+3.090.041
284GLYATL1glycine-N-acyltransferase-like 1Colon+3.080.007
285TLR4toll-like receptor 4Colon+3.080.001
286CFIcomplement factor IColon+3.070.027
287SRPX2sushi-repeat containing protein, X-linked 2Colon+3.050.002
288NLRP11NLR family, pyrin domain containing 11Colon+3.030.001
290ZNF446zinc finger protein 446Colon+3.010.001
291SPATA6Lspermatogenesis associated 6-likeColon+3.010.001

Search GEO for disease gene expression data for Colorectal Cancer.

Pathways for genes affiliated with Colorectal Cancer

About this section

Pathways related to Colorectal Cancer according to GeneCards Suite gene sharing:

(show top 50)    (show all 162)
idSuper pathways (with members indented)ScoreTop Affiliating Genes
Show member pathways
Signal transduction PTEN pathway59
311.4BUB1B, APC, TP53, EP300, AKT1, CCND1
Show member pathways
Show member pathways
Show member pathways
Proteasome Degradation36
Immune response Antigen presentation by MHC class I59
Show member pathways
Signaling Pathways in Glioblastoma36
11.3CTNNB1, EP300, TP53, PIK3CA, FGFR3, AKT1
Show member pathways
DNA damage response (only ATM dependent)36
Wnt Signaling Pathway and Pluripotency36
11.2AXIN2, CCND1, AKT1, EP300, APC, TP53
1111.2TP53, AURKA, EP300, AKT1, CCND1, BAX
Show member pathways
11.2FGFR3, BAX, NRAS, CCND1, AKT1, EP300
Show member pathways
Wnt Signaling Pathway NetPath36
11.1AXIN2, AKT1, CTNNB1, CCND1, EP300, TP53
1611.1TP53, EP300, CCND1, PIK3CA, NRAS, FGFR3
1711.1NRAS, CTNNB1, AKT1, TP53, EP300, PIK3CA
Show member pathways
11.1TP53, EP300, BRAF, AKT1, CCND1, NRAS
Show member pathways
Show member pathways
11.1NRAS, AKT1, BAX, EP300, BRAF, TP53
Show member pathways
11.1EP300, NRAS, TP53, AKT1, BRAF, BAX
Show member pathways
Show member pathways
Toll-like receptor signaling pathway36
Regulation of toll-like receptor signaling pathway36
Show member pathways
Integrin-mediated cell adhesion36
Focal Adhesion36
Show member pathways
Show member pathways
11.0AXIN2, CTNNB1, APC, TP53, EP300, NRAS
Show member pathways
ErbB receptor signaling network36
ErbB signaling pathway36
Show member pathways
Show member pathways
PLK2 and PLK4 events36
Polo-like kinase signaling events in the cell cycle36
3011.0NRAS, CCND1, AKT1, TP53, PIK3CA, FGFR3
Show member pathways
Development EGFR signaling via PIP359
Development PDGF signaling via MAPK cascades59
Apoptosis and survival Anti apoptotic action of membrane bound ESR159
Signaling of Hepatocyte Growth Factor Receptor36
Development EGFR signaling via small GTPases59
Development Neurotrophin family signaling59
Apoptosis and survival NGF signaling pathway59
Apoptosis and survival Role of CDK5 in neuronal death and survival59
Show member pathways
3411.0PIK3CA, EP300, TP53, CCND1, NRAS, BAX
Show member pathways
Prolactin Signaling Pathway36
Development Prolactin receptor signaling59
Leptin signaling pathway36
3611.0AXIN2, CTNNB1, APC, CCND1, EP300
3711.0TP53, EP300, CCND1, CTNNB1, AXIN2
Show member pathways
Translation Non genomic rapid action of Androgen Receptor59
11.0EP300, PIK3CA, AKT1, CCND1, CTNNB1
Show member pathways
Development ERBB family signaling59
Development GDNF family signaling59
Show member pathways
IL-9 Signaling Pathway36
Development Thrombopoietin regulated cell processes59
IL-7 Signaling Pathway36
Immune response IL 9 signaling pathway59
Show member pathways
4411.0TP53, BRAF, AKT1, NRAS, PIK3CA
Show member pathways
Development IGF RI signaling
Immune response IL 4 signaling pathway59
Signal transduction AKT signaling59
11.0AKT1, PIK3CA, CCND1, TP53, BAX
Show member pathways
Prostate Cancer36
Integrated Cancer pathway36
Steroid Biosynthesis36
11.0BAX, CCND1, AKT1, TP53, PIK3CA
Show member pathways
11.0TP53, EP300, AKT1, CCND1, BAX
Show member pathways
Show member pathways

Compounds for genes affiliated with Colorectal Cancer

About this section

Compounds related to Colorectal Cancer according to GeneCards Suite gene sharing:

(show top 50)    (show all 141)
idCompoundScoreTop Affiliating Genes
1serine4412.2AKT1, ODC1, CTNNB1, CCND1, FGFR3, AURKA
2tyrosine4412.0AKT1, FGFR3, BRAF, ODC1, PTPRJ, PIK3CA
3threonine4412.0FGFR3, AXIN2, CTNNB1, CCND1, AKT1, EP300
4estrogen4412.0PIK3CA, CCND1, AURKA, ODC1, TP53, BAX
5paclitaxel44 50 1113.9ODC1, BRAF, BUB1B, AURKA, PIK3CA, TP53
6doxorubicin44 50 1113.9CTNNB1, FGFR3, AKT1, CCND1, BAX, EP300
7retinoic acid44 2412.8CCND1, CTNNB1, BAX, AKT1, EP300, BRAF
8paraffin4411.8AKT1, FGFR3, CTNNB1, BAX, CCND1, BRAF
9vegf4411.7FGFR3, CTNNB1, AKT1, CCND1, EP300, BRAF
10curcumin4411.7TP53, APC, ODC1, CTNNB1, CCND1, AKT1
11sb 20358044 6012.7CCND1, EP300, TP53, CTNNB1, BAX, AKT1
12rapamycin4411.7PIK3CA, CTNNB1, CCND1, AKT1, FLCN, BRAF
13ly2940024411.7EP300, CTNNB1, BAX, CCND1, AKT1, BRAF
14wortmannin4411.7EP300, CTNNB1, BAX, CCND1, PIK3CA, APC
15cisplatin44 50 60 1114.6BRAF, CTNNB1, BAX, CCND1, AKT1, EP300
16resveratrol44 60 24 1114.6PIK3CA, CTNNB1, ODC1, BAX, CCND1, EP300
17adriamycin4411.6BAX, CCND1, EP300, TP53, ODC1, CTNNB1
18agar4411.5CTNNB1, CCND1, AKT1, ODC1, PIK3CA, BRAF
19arginine4411.5FGFR3, ODC1, TP53, BRAF, EP300, AKT1
20phosphatidylinositol4411.5PIK3CA, EP300, APC, CTNNB1, BRAF, BAX
21butyrate4411.5CCND1, EP300, TP53, BAX, CTNNB1, AKT1
22tamoxifen44 50 28 1114.5TP53, CTNNB1, BAX, AKT1, PIK3CA, CCND1
23pd 98,0594411.5BRAF, EP300, AKT1, BAX, CTNNB1, CCND1
24crcs4411.5PIK3CA, APC, TP53, BRAF, CTNNB1, CCND1
25indole-3-carbinol4411.5CTNNB1, TP53, BAX, CCND1, ODC1, AKT1
26sulindac44 1112.5CCND1, BAX, CTNNB1, APC, ODC1, TP53
27egcg4411.4TP53, CCND1, BAX, CTNNB1, PIK3CA, ODC1
28arsenite44 2412.4PIK3CA, TP53, AKT1, CTNNB1, CCND1, BAX
29guanine44 24 1113.4APC, TP53, FGFR3, AKT1, CTNNB1, CCND1
30retinoid4411.4EP300, TP53, ODC1, BAX, CTNNB1, CCND1
31cycloheximide4411.4BAX, CTNNB1, CCND1, AKT1, APC, TP53
32depsipeptide4411.3BAX, CCND1, EP300, BRAF, TP53
33matrigel4411.3ODC1, PIK3CA, BRAF, AKT1, CCND1, CTNNB1
34progesterone44 28 60 24 1115.3CTNNB1, EP300, PIK3CA, CCND1, BRAF, TP53
35n acetylcysteine4411.3CTNNB1, BAX, CCND1, AKT1, TP53, ODC1
36celecoxib44 60 28 50 24 1116.3CTNNB1, BAX, CCND1, AKT1, APC
37adpribose4411.3PIK3CA, TP53, CCND1, CTNNB1, BAX
38azoxymethane4411.3CCND1, APC, ODC1, CTNNB1
39nocodazole44 1112.2APC, AKT1, CTNNB1, BUB1B, TP53
40exisulind4411.2CCND1, CTNNB1, BAX, APC
41vincristine44 50 1113.2ODC1, TP53, AKT1, CCND1, BAX
42testosterone44 60 24 1114.1CCND1, CTNNB1, EP300, APC, ODC1, PIK3CA
43bromodeoxyuridine4411.1CCND1, ODC1, EP300, PIK3CA, CTNNB1
44samp4411.1AXIN2, APC, CTNNB1
45mg 13244 6012.1CCND1, CTNNB1, AKT1, BAX, TP53
46quercetin44 60 24 1114.0CCND1, BAX, AKT1, PIK3CA, CTNNB1
471,2-dimethylhydrazine4411.0APC, CTNNB1, ODC1
48imatinib44 50 1113.0CCND1, FGFR3, CTNNB1, PIK3CA, BRAF
49glycogen44 2412.0APC, CCND1, CTNNB1, AXIN2, AKT1, PIK3CA
50actinomycin d4410.7PIK3CA, BAX, EP300, TP53, AKT1, ODC1

GO Terms for genes affiliated with Colorectal Cancer

About this section

Cellular components related to Colorectal Cancer according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1nucleusGO:000563411.8MLH3, AURKA, APC, TP53, BRAF, FLCN
2cytosolGO:000582911.8CTNNB1, PIK3CA, AURKA, BUB1B, ODC1, APC
3plasma membraneGO:000588611.5PIK3CA, PTPRJ, APC, DCC, BRAF, FLCN
4beta-catenin destruction complexGO:003087710.9APC, CTNNB1, AXIN2
5lamellipodiumGO:003002710.8CTNNB1, APC, PIK3CA
6centrosomeGO:000581310.8AURKA, APC, CTNNB1, AXIN2
7protein-DNA complexGO:003299310.4CTNNB1, EP300

Biological processes related to Colorectal Cancer according to GeneCards Suite gene sharing:

(show all 47)
idNameGO IDScoreTop Affiliating Genes
1apoptotic processGO:000691511.7DCC, APC, BUB1B, EP300, CTNNB1, BAX
2positive regulation of apoptotic processGO:004306511.6DCC, AKT1, BAX, CTNNB1, APC, FLCN
3negative regulation of transcription from RNA polymerase II promoterGO:000012211.5FLCN, TP53, FGFR3, EP300, CTNNB1, CCND1
4innate immune responseGO:004508711.5PIK3CA, CTNNB1, EP300, NRAS, FGFR3, AKT1
5positive regulation of protein phosphorylationGO:000193411.4CCND1, FLCN, EP300, AKT1, AXIN2
6phosphatidylinositol-mediated signalingGO:004801511.4AURKA, FGFR3, PIK3CA, AKT1, BUB1B
7fibroblast growth factor receptor signaling pathwayGO:000854311.4AKT1, BRAF, FGFR3, NRAS, PIK3CA
8neurotrophin TRK receptor signaling pathwayGO:004801111.4AKT1, NRAS, BRAF, PIK3CA, FGFR3
9negative regulation of cell proliferationGO:000828511.4PTPRJ, TP53, CTNNB1, AXIN2, APC
10blood coagulationGO:000759611.3PTPRJ, TP53, AKT1, NRAS, PIK3CA
11negative regulation of neuron apoptotic processGO:004352411.3NRAS, BRAF, BAX, PIK3CA
12insulin receptor signaling pathwayGO:000828611.3NRAS, PIK3CA, AKT1, FGFR3
13Fc-epsilon receptor signaling pathwayGO:003809511.3AKT1, NRAS, FGFR3, PIK3CA
14epidermal growth factor receptor signaling pathwayGO:000717311.2PIK3CA, NRAS, FGFR3, AKT1
15positive regulation of transcription from RNA polymerase II promoterGO:004594411.2TP53, FLCN, EP300, CTNNB1, AKT1
16protein kinase B signalingGO:004349111.2AKT1, EP300, PIK3CA
17T cell differentiation in thymusGO:003307711.2CTNNB1, TP53, APC
18positive regulation of cell adhesionGO:004578511.2FLCN, APC, PTPRJ
19positive regulation of neuron apoptotic processGO:004352511.2BAX, TP53, FGFR3
20positive regulation of peptidyl-serine phosphorylationGO:003313811.1BRAF, PIK3CA, AKT1
21intrinsic apoptotic signaling pathwayGO:009719311.1BAX, AKT1, TP53
22canonical Wnt signaling pathwayGO:006007011.1APC, CTNNB1, CCND1
23liver developmentGO:000188911.1EP300, CCND1, CTNNB1
24cell proliferationGO:000828311.1BUB1B, TP53, AKT1, AXIN2
25cellular response to hypoxiaGO:007145611.1TP53, EP300, AKT1
26kidney developmentGO:000182211.1ODC1, APC, BAX
27regulation of centromeric sister chromatid cohesionGO:007060211.1CTNNB1, AXIN2
28positive regulation of ERK1 and ERK2 cascadeGO:007037411.1FGFR3, DCC, BRAF
29response to UV-AGO:007014111.1CCND1, AKT1
30neuron migrationGO:000176411.1DCC, BAX, CTNNB1
31canonical Wnt signaling pathway involved in negative regulation of apoptotic processGO:004433611.0CTNNB1, APC
32metaphase/anaphase transition of mitotic cell cycleGO:000709111.0BUB1B, APC
33dorsal/ventral axis specificationGO:000995011.0AXIN2, CTNNB1
34positive regulation of protein oligomerizationGO:003246111.0TP53, BAX
35mitotic G1 DNA damage checkpointGO:003157111.0TP53, CCND1
36mitotic cell cycleGO:000027811.0AURKA, CCND1, BUB1B, EP300
37negative regulation of cell growthGO:003030811.0FLCN, PTPRJ, TP53
38striated muscle cell differentiationGO:005114610.9AKT1, NRAS
39Notch signaling pathwayGO:000721910.9EP300, CCND1, TP53
40lens morphogenesis in camera-type eyeGO:000208910.9FGFR3, CTNNB1
41response to salt stressGO:000965110.9BAX, TP53
42negative regulation of apoptotic signaling pathwayGO:0200123410.8BAX, CTNNB1
43spindle organizationGO:000705110.7BUB1B, AURKA
44response to X-rayGO:001016510.7TP53, CCND1
45positive regulation of cell deathGO:001094210.7AXIN2, EP300
46apoptotic mitochondrial changesGO:000863710.6BAX, AKT1
47intrinsic apoptotic signaling pathway by p53 class mediatorGO:007233210.4TP53, BAX

Molecular functions related to Colorectal Cancer according to GeneCards Suite gene sharing:

(show all 15)
idNameGO IDScoreTop Affiliating Genes
1protein bindingGO:000551512.4AKT1, AXIN2, CTNNB1, BAX, CCND1, EP300
2ATP bindingGO:000552411.4TP53, PIK3CA, MLH3, FGFR3, AURKA, BUB1B
3protein kinase bindingGO:001990111.4CCND1, CTNNB1, AXIN2, APC, PTPRJ, AURKA
4protein complex bindingGO:003240311.2CTNNB1, EP300, NRAS, CCND1, FLCN
5protein kinase activityGO:000467211.2AURKA, BUB1B, AKT1, CCND1, BRAF
6enzyme bindingGO:001989911.2CCND1, TP53, AKT1, CTNNB1, AXIN2
7identical protein bindingGO:004280211.1BRAF, DCC, TP53, BAX, AKT1
8beta-catenin bindingGO:000801311.1AXIN2, PTPRJ, APC, EP300
9transcription factor bindingGO:000813411.0TP53, EP300, CCND1, CTNNB1
10protein serine/threonine kinase activityGO:000467411.0AKT1, BRAF, BUB1B, PIK3CA
11chromatin bindingGO:000368210.8EP300, TP53, MLH3, CTNNB1
12I-SMAD bindingGO:007041110.7CTNNB1, AXIN2
13nuclear hormone receptor bindingGO:003525710.7EP300, CTNNB1
14gamma-catenin bindingGO:004529510.7PTPRJ, APC
15mitogen-activated protein kinase bindingGO:005101910.4EP300, PTPRJ

Sources for Colorectal Cancer

About this section
26ICD10 via Orphanet
34MESH via Orphanet
47OMIM via Orphanet
57SNOMED-CT via Orphanet
62UMLS via Orphanet